OverviewSuggest Edit

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats, and horses. Its lead product candidates are the intravenous, or IV, form of Zimeta (dipyrone injection), previously known as KIND-012, for the control of pyrexia (fever) in horses and Mirataz (mirtazapine transdermal ointment), formerly known as KIND-010, for management of weight loss in cats. In addition, the Company has other product candidates, including several biologics, in various stages of development.

TypePublic
Founded2013
HQBurlingame, US
Websitekindredbio.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2018)146(+132%)
Revenue (FY, 2019)$4.3 M(+117%)
Share Price (Mar 2020)$4.1 (-9%)

Key People/Management at Kindred Biosciences

Hangjun Zhan

Hangjun Zhan

Chief Scientific Officer
Wendy Wee

Wendy Wee

CFO
Karen Greenwood

Karen Greenwood

Vice President of Project Management
Katja Buhrer

Katja Buhrer

Vice President of Corporate Development and Investor Relations
Melinda Poole O'Banion

Melinda Poole O'Banion

Executive Director of Clinical Development and Regulatory Affairs
Kathy Vannatta

Kathy Vannatta

Senior Director, Regulatory Affairs
Show more

Kindred Biosciences Office Locations

Kindred Biosciences has offices in Burlingame, San Diego and Wathena
Burlingame, US (HQ)
1555 Old Bayshore Hwy #200
Burlingame, US
863 Mitten Rd Suite 100 G
San Diego, US
591 Camino De La Reina #407
Wathena, US
1411 Oak St
Show all (4)

Kindred Biosciences Financials and Metrics

Kindred Biosciences Revenue

Kindred Biosciences's revenue was reported to be $4.26 m in FY, 2019
USD

Revenue (FY, 2019)

4.3m

Gross profit (FY, 2019)

3.7m

Gross profit margin (FY, 2019), %

86.2%

Net income (FY, 2019)

(61.4m)

EBIT (FY, 2019)

(62.6m)

Market capitalization (27-Mar-2020)

160.3m

Closing stock price (27-Mar-2020)

4.1

Cash (31-Dec-2019)

16.0m

EV

166.8m
Kindred Biosciences's current market capitalization is $160.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.0m4.3m

Cost of goods sold

324.0k587.0k

Gross profit

1.6m3.7m

Gross profit Margin, %

84%86%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

640.0k515.0k1.2m1.1m

Cost of goods sold

110.0k92.0k169.0k139.0k

Gross profit

530.0k423.0k1.1m965.0k

Gross profit Margin, %

83%82%86%87%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.0m20.0m6.7m34.8m56.3m16.0m

Accounts Receivable

903.0k923.0k

Prepaid Expenses

797.0k1.7m2.5m

Inventories

1.9m1.8m3.6m4.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

36.5m9.3m8.3m5.4m14.8m4.5m9.6m16.0m13.3m19.9m36.9m43.6m44.5m85.4m70.0m68.6m32.0m39.2m

Accounts Receivable

2.1m492.0k242.0k275.0k937.0k801.0k

Prepaid Expenses

565.0k532.0k688.0k591.0k443.0k449.0k862.0k899.0k887.0k1.2m1.2m911.0k1.4m1.5m1.5m1.9m1.9m1.5m

Inventories

2.5m4.5m4.4m4.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(120.0k)(27.1m)(5.8m)(30.9m)(49.7m)(61.4m)

Depreciation and Amortization

146.0k155.0k475.0k805.0k2.5m

Inventories

(14.1m)16.0m(37.9m)(3.6m)(648.0k)

Accounts Payable

6.0k30.0k(710.0k)1.3m277.0k1.8m
USDY, 2019

EV/EBIT

-2.7 x

EV/CFO

-3 x

Financial Leverage

1.4 x
Show all financial metrics

Kindred Biosciences Online and Social Media Presence

Embed Graph

Kindred Biosciences News and Updates

Kindred Biosciences annonce que la Commission européenne a approuvé la pommade transdermique Mirataz® 20 mg/g pour chats présentant un faible appétit et une perte de poids

- Mirataz est le premier et le seul médicament approuvé dans l'Union européenne pour soigner les chats présentant un faible appétit et une perte de poids résultant de pathologies chroniques. SAN FRANCISCO, 21 décembre 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (Nasdaq : KIN), société...

Kindred Biosciences snags $50 mln debt facility

Kindred Biosciences, a biopharmaceutical company focused on pets, has secured a $50 million debt facility from Solar Capital Partners LLC and Cantor Fitzgerald & Co acted as sole lead arranger and financial adviser to KindredBio on this transaction.

Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program

SAN FRANCISCO, Sept. 10, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company developing novel drugs and biologics, today announced that it has been selected by the National Cancer Institute (NCI) as one of three contractors in...

Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational

SAN FRANCISCO, May 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Institutional Investor Conference taking place May 22nd in Beverly...

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York...

Kindred Biosciences Announces Pricing of Public Offering

SAN FRANCISCO, Jan. 18, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a ...
Show more

Kindred Biosciences Blogs

Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs

San Francisco, California (March 24, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4…

Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results

San Francisco, California (March 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront…

Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results

Monday, March 16, 2020 Time of Event: 4:30 p.m. Eastern time/1:30 p.m. Pacific time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID:  2367136 For more information about this event, please see the press release. The post Event: Kindred Bioscien…

Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, March 16, 2020. San Francisco, California (March 3, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets,…

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit

San Francisco, California (February 18, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch Animal Health Summit on February 24 in New York City. Dr. Richard…

Kindred Biosciences Announces Half-Life Extension Technology for Canine Antibodies

Positive results from canine pharmacokinetic study demonstrate up to three-fold increase in antibody half-life. Longer half-lives have the potential to reduce dosing frequency, lower doses, and/or reduce cost of goods sold. Technology expected to lead to multiple best-in-class products. San Francisc…
Show more

Kindred Biosciences Frequently Asked Questions

  • When was Kindred Biosciences founded?

    Kindred Biosciences was founded in 2013.

  • Who are Kindred Biosciences key executives?

    Kindred Biosciences's key executives are Hangjun Zhan, Wendy Wee and Karen Greenwood.

  • How many employees does Kindred Biosciences have?

    Kindred Biosciences has 146 employees.

  • What is Kindred Biosciences revenue?

    Latest Kindred Biosciences annual revenue is $4.3 m.

  • What is Kindred Biosciences revenue per employee?

    Latest Kindred Biosciences revenue per employee is $29.2 k.

  • Who are Kindred Biosciences competitors?

    Competitors of Kindred Biosciences include Madam Therapeutics, ECO Animal Health Group and Napo Pharmaceuticals.

  • Where is Kindred Biosciences headquarters?

    Kindred Biosciences headquarters is located at 1555 Old Bayshore Hwy #200, Burlingame.

  • Where are Kindred Biosciences offices?

    Kindred Biosciences has offices in Burlingame, San Diego and Wathena.

  • How many offices does Kindred Biosciences have?

    Kindred Biosciences has 4 offices.